Skip to content

The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities

The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06838325
Enrollment
24
Registered
2025-02-20
Start date
2025-02-06
Completion date
2025-10-29
Last updated
2025-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer Screening

Brief summary

To learn about barriers to prostate cancer screening in Black, faith-based communities. Investigators will use the information collected in this study to create a prostate cancer education program that is relevant to Black men within the church and improve prostate cancer screening.

Detailed description

Primary Objective To determine barriers to prostate cancer screening in Black faith-based communities through focus group assessments which will inform a culturally relevant prostate cancer education and early detection program.

Interventions

OTHERProstate Cancer Screening

The focus group will take about 2 hours to complete and will be led by the study Investigator and a research coordinator. A member of the research team will also take notes during the focus group, and the discussion will also be audio recorded and transcribed (written down word for word). Additionally, participant demographic information will be collected (such as your age).

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Self-reported identification of Black/ African American * Willingness to participate in the study with signed and dated informed consent

Exclusion criteria

* Non-english proficiency * Unwillingness to participate in the study or inability to sign and date an informed consent

Design outcomes

Primary

MeasureTime frame
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion, an average of 1 year.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026